Health committee  Yes. Mr. Matthew Kellway —that this is the kind of bargain. Okay. That's helpful for me to understand. Dr. Morgan, as I understood your statement, you were suggesting that the way to increase innovation in Canada was to build capacity and that will attract private investment.

Health committee  One of the main collaborations that I think we need to recognize right now is the sharing of clinical data. The European Medicines Agency is going forward by making full disclosure of all clinical data for drugs and medical devices, starting in 2014. On disclosure of data and on

Health committee  —and I think this is maybe the first thing that needs to be done, sir.

Health committee  The thing is that the deal is kind of dead now.

Health committee  I don't know.... Basically, we're not enforcing it any more. Drug companies say, “Well, you know, things are different now so this is normal, and we're not respecting the deal anymore.” For me, what it would mean, basically, is that if the deal is dead from the side of drug compa

Health committee  Right now, CADTH assesses health technologies. It could be given more resources to share its research findings with all doctors.

Health committee  Something very simple could be done: address the culture of marketing-based medicine by favouring evidence-based medicine.

Health committee  In terms of medical devices in the pharmaceutical sector, we still have a lot of regulations. Sometimes there is maybe too much regarding some issues; sometimes not enough on other issues. As for medical devices, the problem is that it's still a bit of the far west out there in t

Health committee  I want to come back to the fact that new drugs are tested against placebos. It is important to understand that the scientific research that the pharmaceutical and medical sectors engage in is set up like a marketing campaign. Private research serves to produce private arguments t

Health committee  In terms of getting bang for the buck, when it comes to innovation policy, I always think it is a bit weird that basically our industrial policy for developing the pharmaceutical sector is based on how much we will pay out of the health budget. For me, the health budget should be

Health committee  First of all, it's important to know how innovation is being defined. Normally, innovation is defined on the basis of patents or financial gain. Financially, the pharmaceutical sector is very innovative. It makes a lot of money. The issue comes into play on the therapeutic side.

Health committee  I think we need federal leadership. In the last two or three years we've massively reduced the price of generics. We've also had the patent cliff, so a lot of the blockbuster drugs turned into generics. So it seems as though the cost containment has been working, but, basically

Health committee  In the U.K. they will implement something interesting called value-based pricing. Basically, instead of paying for drugs, they will pay for the health outcomes related to these drugs, which is something completely different. You don't pay for the product, you pay for health outco

Health committee  Perfect, and I'm sure Steve will be able to add something as well. Value-based pricing is very interesting. You pay for the health outcomes and not for the products. What we negotiate with the drug companies is how much they will contribute to improving the health of the populat

Health committee  There are two things. To get a drug approved for the market, you simply need to compare it to a placebo and show that its has more benefits than the placebo has. But then to get the drug, especially on provincial public formularies, you need to prove minimally that you can get so